Mumbai-based Lupin launched the generic version of Allergan’s contraceptive pill, Minastrin, in the US, with an 180-day sales exclusivity. The product has a market size of $361 million and will provide the Indian company significant profit opportunity.
This is the fifth product launch by the company in the last 15 days and the ninth one since its Goa plant got a final approval from the US Food and Drug Administration (USFDA) in November. These product launches come at a time when Indian generic makers are facing pricing pressure in US markets.
“The company is significantly dependent on two products (Glumetza and Fortamet),